^
    2ms
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    3ms
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    11ms
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2026 --> Apr 2025
    Enrollment open • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    1year
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Not yet recruiting, Amgen
    New P1 trial • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305